- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01799031
Educational Intervention for Reducing Work Disability in Breast Cancer Survivors
Reducing Work Disability in Breast Cancer Survivors
Studieoversikt
Status
Forhold
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. Determine the feasibility and usability of the Work Ability Improvement Through Symptom Management and Ergonomic Strategies (WISE) and empirically evaluate its effect on short-term work ability among breast cancer survivors (BCS).
SECONDARY OBJECTIVES:
I. Explore individual and workplace factors associated with work ability in BCS.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive access to the WISE web-based educational intervention to help BCS manage their symptoms, identify ergonomic workplace problems and risks, and implement ergonomic modifications. Patients also receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
ARM II: Patients receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
After completion of study treatment, patients are followed up at 3 and 6 months.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53792
- University of Wisconsin Hospital and Clinics
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnosed with breast cancer
- Employed at time of cancer diagnosis (defined as paid employment > 20 hours/week)
- Within six months of completion of active treatment
- Working during treatment or intending to return to work following active treatment
- Computer and internet access
Exclusion Criteria:
- Patients who do not intend to continue/resume working following treatment
- Develop distant metastases or progressive disease
- Prior diagnosis of malignancy at any other site except for in situ carcinomas of the cervix or non-melanomatous skin cancers
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Arm I (WISE)
Patients receive access to the WISE web-based educational intervention to help BCS manage their symptoms, identify ergonomic workplace problems and risks, and implement ergonomic modifications.
Patients also receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
|
Hjelpestudier
Hjelpestudier
Andre navn:
Receive access to the WISE web-based educational intervention
Receive standard of care
Andre navn:
Receive access to the WISE web-based educational intervention
Andre navn:
|
|
Aktiv komparator: Arm II (control)
Patients receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
|
Hjelpestudier
Hjelpestudier
Andre navn:
Receive standard of care
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Usability of the WISE website as assessed by responses to a 5-point Likert scale
Tidsramme: 3 months
|
The primary analysis of the effect of the WISE intervention on work ability will be performed using a Wilcoxon rank sum test.
|
3 months
|
|
Usability of the WISE website as assessed by responses to a 5-point Likert scale
Tidsramme: 6 months
|
The primary analysis of the effect of the WISE intervention on work ability will be performed using a Wilcoxon rank sum test.
|
6 months
|
|
Work ability, assessed by the Work Limitations Questionnaire (WLQ)
Tidsramme: Baseline
|
Baseline
|
|
|
Work ability, assessed by the WLQ
Tidsramme: 3 months
|
3 months
|
|
|
Work ability, assessed by the WLQ
Tidsramme: 6 months
|
6 months
|
|
|
Individual factors, including symptoms assessed using the Symptom Bother-Revised scale (SB-R) and MD Anderson Symptom Inventory (MDASI), socio-demographic factors, individual disease factors, and treatment factors
Tidsramme: Baseline
|
Baseline
|
|
|
Individual factors, including symptoms assessed using the SB-R and MDASI, socio-demographic factors, individual disease factors, and treatment factors
Tidsramme: 3 months
|
3 months
|
|
|
Individual factors, including symptoms assessed using the SB-R and MDASI, socio-demographic factors, individual disease factors, and treatment factors
Tidsramme: 6 months
|
6 months
|
|
|
Workplace factors, including work history, job characteristics, job control, job support, and level of job stress using the Job Content Questionnaire (JCQ)
Tidsramme: Baseline
|
Baseline
|
|
|
Workplace factors, including work history, job characteristics, job control, job support, and level of job stress using the JCQ
Tidsramme: 3 months
|
3 months
|
|
|
Workplace factors, including work history, job characteristics, job control, job support, and level of job stress using the JCQ
Tidsramme: 6 months
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Feasibility measures, including participation/dropout rates, patient satisfaction, usability/satisfaction with WISE, knowledge/use of self-care symptom management/ergonomic strategies, and use of ergonomic/symptom management strategies, and barriers
Tidsramme: Up to 6 months
|
Up to 6 months
|
|
Self-car symptom management strategies used (if any), workplace strategies implemented, and barriers to implementation
Tidsramme: Up to 6 months
|
Up to 6 months
|
|
Individuals self-reported work ability, using the Work Ability Index (WAI)
Tidsramme: Up to 6 months
|
Up to 6 months
|
|
Employment status
Tidsramme: Up to 6 months
|
Up to 6 months
|
|
Change in job performance or difficulty performing work tasks
Tidsramme: Baseline to 6 months
|
Baseline to 6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Mary Sesto, University of Wisconsin, Madison
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- OS12115
- A536130 (Annen identifikator: UW Madison)
- NCI-2012-03055 (Registeridentifikator: NCI Trial ID)
- 2012-0729 (Annen identifikator: Institutional Review Board)
- SMPH\ORTHOPEDIC&REHAB\PT (Annen identifikator: UW Madison)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Brystkreft
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Cancer Institute and Hospital, Chinese Academy...Rekruttering
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)FullførtAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Sør -Korea
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Fondazione... og andre samarbeidspartnereRekrutteringBrystkreft | Brystneoplasmer | Bryst sykdommer | Neoplasma i brystet | Brystsvulster | Brystkarsinom | Brystneoplasmer, mannlige | Brystkreft stadium IV | Hormonreseptorpositiv ondartet neoplasma i brystet | HR-positiv brystkreft | Hormonreseptorpositivt brystkarsinom | Hormonreseptor (HR)-positiv brystkreft | Hormonreseptorpositiv... og andre forholdItalia
-
University of California, DavisNational Cancer Institute (NCI)SuspendertAnatomisk stadium III brystkreft AJCC v8 | Avansert malignt solid neoplasma | Stadium III lungekreft AJCC v8 | Stadium IV lungekreft AJCC v8 | Stadium III nyrecellekreft AJCC v8 | Stadium IV nyrecellekreft AJCC v8 | Klinisk stadium III kutant melanom AJCC v8 | Trinn IV tykktarmskreft AJCC v8 | Klinisk stadium... og andre forholdForente stater
Kliniske studier på spørreskjemaadministrasjon
-
Radboud University Medical CenterHoffmann-La RocheRekrutteringMembranøs nefropati - PLA2R-indusertNederland
-
Hospital NordRekrutteringEvaluering av variasjonen av sub-pulmonal hastighet-tid integral for å forutsi væskens reaksjonsevneFluid Responsibility Forutsigbarhet | Væske gjenopplivingFrankrike
-
Virginia Commonwealth UniversityRigel PharmaceuticalsRekrutteringAkutt myeloid leukemiForente stater
-
Tang-Du HospitalHar ikke rekruttert ennå
-
University of CalgaryHar ikke rekruttert ennåKoronararteriesykdom | Hjertefeil | Diabetes mellitus | Kroniske lungesykdommer | NyresykdomCanada
-
Asian Institute of Gastroenterology, IndiaRekrutteringCrohns sykdom (CD) | Perianal Crohns sykdomIndia
-
AkesoHar ikke rekruttert ennåUrotelial karsinom (UC)Kina
-
Qilu Pharmaceutical Co., Ltd.Har ikke rekruttert ennåProstatakreft
-
Guangzhou Virotech Pharmaceutical Co., Ltd.RekrutteringDiffus Intrinsic Pontine Glioma | Diffus midtlinjegliom, H3 K27M-mutantKina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Har ikke rekruttert ennåChildren Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease